230 related articles for article (PubMed ID: 17030370)
1. The use of myocardial and testicular end points as a basis for estimating a proposed tolerable daily intake for sodium monofluoroacetate (1080).
Foronda NM; Fowles J; Smith N; Taylor M; Temple W; Darlington C
Regul Toxicol Pharmacol; 2007 Feb; 47(1):29-36. PubMed ID: 17030370
[TBL] [Abstract][Full Text] [Related]
2. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
Foronda NM; Fowles J; Smith N; Taylor M; Temple W
Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
[TBL] [Abstract][Full Text] [Related]
3. Background to the ADI/TDI/PTWI.
Herrman JL; Younes M
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S109-13. PubMed ID: 10597623
[TBL] [Abstract][Full Text] [Related]
4. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
Zhu Y; Wang T; Jelsovsky JZ
Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
[TBL] [Abstract][Full Text] [Related]
5. Precision of estimates of an ADI (or TDI or PTWI).
Speijers GJ
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
[TBL] [Abstract][Full Text] [Related]
6. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
Filipsson AF; Sand S; Nilsson J; Victorin K
Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
[TBL] [Abstract][Full Text] [Related]
7. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
Bokkers BG; Slob W
Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
[TBL] [Abstract][Full Text] [Related]
8. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
Sand S; Victorin K; Filipsson AF
J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
[TBL] [Abstract][Full Text] [Related]
9. Toxicity value for 3-monochloropropane-1,2-diol using a benchmark dose methodology.
Hwang M; Yoon E; Kim J; Jang DD; Yoo TM
Regul Toxicol Pharmacol; 2009 Mar; 53(2):102-6. PubMed ID: 19133308
[TBL] [Abstract][Full Text] [Related]
10. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
11. Procedures for calculating benchmark doses for health risk assessment.
Gaylor D; Ryan L; Krewski D; Zhu Y
Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
[TBL] [Abstract][Full Text] [Related]
12. Development of an occupational exposure limit for n-propylbromide using benchmark dose methods.
Stelljes ME; Wood RR
Regul Toxicol Pharmacol; 2004 Oct; 40(2):136-50. PubMed ID: 15450717
[TBL] [Abstract][Full Text] [Related]
13. Toxicological analysis points to a lower tolerable daily intake of melamine in food.
Hsieh DP; Chiang CF; Chiang PH; Wen CP
Regul Toxicol Pharmacol; 2009 Oct; 55(1):13-6. PubMed ID: 19486917
[TBL] [Abstract][Full Text] [Related]
14. The use of an additional safety or uncertainty factor for nature of toxicity in the estimation of acceptable daily intake and tolerable daily intake values.
Renwick AG
Regul Toxicol Pharmacol; 1995 Dec; 22(3):250-61. PubMed ID: 8837849
[TBL] [Abstract][Full Text] [Related]
15. Incidence and severity in relation to magnitude of intake above the ADI or TDI: use of critical effect data.
Renwick AG
Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S79-86. PubMed ID: 10597618
[TBL] [Abstract][Full Text] [Related]
16. A procedure for developing risk-based reference doses.
Gaylor DW; Kodell RL
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
[TBL] [Abstract][Full Text] [Related]
17. The benchmark dose approach in food risk assessment: is it applicable and worthwhile?
Muri SD; Schlatter JR; Brüschweiler BJ
Food Chem Toxicol; 2009 Dec; 47(12):2906-25. PubMed ID: 19682530
[TBL] [Abstract][Full Text] [Related]
18. Relation between benchmark dose and no-observed-adverse-effect level in clinical research: effects of daily alcohol intake on blood pressure in Japanese salesmen.
Dakeishi M; Murata K; Tamura A; Iwata T
Risk Anal; 2006 Feb; 26(1):115-23. PubMed ID: 16492185
[TBL] [Abstract][Full Text] [Related]
19. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
Reiss R; Gaylor D
Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
[TBL] [Abstract][Full Text] [Related]
20. Safety assessment of boron by application of new uncertainty factors and their subdivision.
Hasegawa R; Hirata-Koizumi M; Dourson ML; Parker A; Ono A; Hirose A
Regul Toxicol Pharmacol; 2013 Feb; 65(1):108-14. PubMed ID: 23137930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
